Cramer Pamela J.

Cramer Pamela J., Chief Human Resources Officer at Rhythm Pharmaceuticals (RYTM), has demonstrated a clear selling bias in her recent insider transactions, with no buys and eight sales totaling $4.83 million in aggregate value since July 2025. Her most significant sale occurred on November 7, 2025, when she disposed of shares worth $1.91 million, followed by additional sales of $371,850 and $351,750 in December and November 2025, respectively. Smaller dispositions in July 2025—including transactions of $600,564.87 and $319,217.34—further reinforced this trend. While some filings show acquisitions of shares through derivative transactions (coded "M"), these were either non-monetary or significantly outweighed by concurrent sales, such as the $137,433.75 and $71,719.60 acquisitions on July 9, 2025, which coincided with much larger disposals. The most recent activity, filed on February 1, 2026, included a $515,631.69 transaction coded as "F" (likely representing an exercise of derivative securities) alongside several non-monetary acquisitions. However, no new open-market purchases have been reported, maintaining the pattern of net divestment. Cramer’s transactions have been exclusively in RYTM stock, with no diversification into other securities. The consistency of sales over the past eight months suggests a strategic reduction in her equity position rather than sporadic rebalancing. The absence of recent buying activity contrasts with her cumulative $655,484.25 in historical purchases, indicating a shift toward liquidity events in recent filings.